Skip to main content

HomeEpithalonLegal status

Educational — Not Legal AdviceReviewed

Is Epithalon legal? FDA status and US regulatory standing

Current status

Compounding nomination withdrawn. Epithalon was nominated for the FDA bulk drug substances compounding list and was previously placed in a safety-review category before the nomination was withdrawn, so it does not appear on the current bulk substances lists.

Primary source: www.fda.gov

Federal legal status

FDA approval status

Epithalon was nominated for the FDA bulk drug substances compounding list and was previously placed in a safety-review category before the nomination was withdrawn, so it does not appear on the current bulk substances lists. Synthetic tetrapeptide (Ala-Glu-Asp-Gly) from Khavinson Institute, Russia. Telomerase activator in research. No FDA approval, no NDA or IND. Not on any FDA list. Research chemical.

Also known as

Epitalon · Epithalamin · Ala-Glu-Asp-Gly

Frequently asked questions

Is Epithalon FDA approved?
Epithalon was nominated for the FDA bulk drug substances compounding list and was previously placed in a safety-review category before the nomination was withdrawn, so it does not appear on the current bulk substances lists. Primary source linked on this page.
Is Epithalon legal to buy?
Epithalon is available in the U.S. as a research-use-only compound. It was nominated for the FDA bulk drug substances compounding list and was previously placed in a safety-review category before the nomination was withdrawn, so it does not appear on the current bulk substances lists. Sale for human consumption is not permitted.
PeptideBase provides educational research tools and provider discovery. It does not provide medical advice, diagnosis, treatment, prescribing guidance, or dosing instructions. Consult a qualified healthcare professional before making health decisions.

Content review: Regulatory status is sourced from the linked primary records and reviewed by the PeptideBase editorial team. This page is educational — not legal or medical advice. Last reviewed: .

Free newsletter

The Peptide Research Digest

Weekly analysis on providers, sourcing and compounds — from the team behind PeptideBase.

No spam. Unsubscribe anytime. Privacy policy.

Free Guide

The Peptide Research Digest

Get our free provider vetting guide — plus weekly research briefings on peptide sourcing, COA verification, and clinical developments.

No spam.